

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. C-3169/1/US		Serial No. 09/451,641		
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant				
				Gao, D. et al.				
				Filing Date November 30, 1999		Group No. 1615		
U.S. PATENT DOCUMENTS								
Examiner Initial*		Document Number	Publication Date	Name of Patentee or Applicant	Class	Subclass	Filing Date if Appropriate	
		4,895,726	Jan 23, 1990	Curtet <i>et al.</i>	424	456		
FOREIGN PATENT DOCUMENTS								
Examiner Initial*		Document Number	Publication Date	Name of Patentee or Applicant	Class	Subclass	Translation	
							Yes	No
		EP 0 001 247	Apr 4, 1979	Kanebo	A61K	9/18		
		EP 0 256 933	Feb 24, 1988	Ethypharm	A61K	31/235		X
		EP 0 330 532	Aug 30, 1989	Fournier Industrie et Santé	A61K	9/16		X
		WO 96/38131	Dec 5, 1996	Glaxo	A61K	9/14		
		WO 00/15195	Mar 23, 2000	Nycomed	A61K	9/16		
OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)								
		Amidon <i>et al.</i> (1995) A theoretical basis for a biopharmaceutical drug classification: the correlation of <i>in vitro</i> drug product dissolution and <i>in vivo</i> bioavailability. <i>Pharmaceutical Research</i> 12(3), 413-420.						
		Ansel (1985) <i>Introduction to Pharmaceutical Dosage Forms</i> , 4th ed. Philadelphia: Lea & Febiger. Page cited: vii (first page of Contents).						
		Aulton, ed. (1988) <i>Pharmaceutics: The Science of Dosage Form Design</i> . Edinburgh: Churchill Livingstone. Pages cited: 8, 156, 311, 330.						
		Basit <i>et al.</i> (2001) The effect of polyethylene glycol 400 on gastrointestinal transit: implications for the formulation of poorly water-soluble drugs. <i>Pharmaceutical Research</i> 18(8), 1146-1150.						
		Bauer <i>et al.</i> (1991) <i>Pharmazeutische Technologie</i> , 3rd ed. Stuttgart: Verlag. Pages cited: 104, 203.						
		Berry & Nash, ed. (1993) <i>Pharmaceutical Process Validation</i> , 2nd ed. New York: Marcel Dekker. Pages cited: 174-181.						
		British Pharmacopoeia 1993. Pages cited: Vol. I, 316; Vol. II, 753.						
		Fincher <i>et al.</i> (1965) Effect of particle size on gastrointestinal absorption of sulfoxazole in dogs. <i>J. Pharm. Sci.</i> 54(5), 704-708.						
		Ghosh <i>et al.</i> (1998) Product development studies on the tablet formulation of ibuprofen to improve bioavailability. <i>Drug Development & Industrial Pharmacy</i> 24(5), 473-477.						
		Gibaldi (1991) <i>Biopharmaceutics and Clinical Pharmacokinetics</i> , 4th ed. Philadelphia: Lea & Febiger. Pages cited: 51, 52, 62.						
		Hubbard <i>et al.</i> (1996) SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute non-surgical pain model. <i>J. Invest. Med.</i> 44(3), 293A.						
		Hubbard <i>et al.</i> (1996) SC-58635 (celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study. <i>Arthritis & Rheumatism</i> 39 (Suppl. 9), S226, abstract 1188.						
Examiner				Date Considered				
*Examiner. Initial if citation considered, whether or not citation is in conformance with MPEP §609, draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. C-3169/1/US	Serial No. 09/451,641
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant Gao, D. <i>et al.</i>	
				Filing Date November 30, 1999	Group No. 1615
OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)					
		Hubbard <i>et al.</i> (1997) Pilot efficacy of SC-58635, a COX-2 selective inhibitor, in rheumatoid arthritis. <i>Arthritis & Rheumatism</i> 40, S51, abstract 125.			
		Kaneniwa <i>et al.</i> (1973) Dissolution of slightly soluble drugs. I. Influence of particle size on dissolution behavior. <i>Chem. Pharm. Bull.</i> 22(8), 1699-1705.			
		Kaneniwa <i>et al.</i> (1978) Dissolution of slightly soluble drugs. IV. Effect of particle size of sulfonamides on <i>in vitro</i> absorption rate, and their relation to solubility. <i>Chem. Pharm. Bull.</i> 26(3), 813-826.			
		Lachman <i>et al.</i> , ed. (1986) <i>The Theory and Practice of Industrial Pharmacy</i> , 3rd ed. Philadelphia: Lea & Febiger. Pages cited: 21-45, 321-328.			
		Levy (1963). Effect of particle size on dissolution and gastrointestinal absorption rates of pharmaceuticals. <i>Amer. J. Pharm.</i> , March 1963, 78-92.			
		List (1985) <i>Arzneiformenlehre</i> , 4th ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft. Pages cited: 210, 523.			
		Martin (1993) <i>Physical Pharmacy</i> , 4th ed. Philadelphia: Lea & Febiger. Pages cited: 331, 423-436.			
		Ridolfo <i>et al.</i> (1979) Benoxaprofen, a new anti-inflammatory agent: particle-size effect on dissolution rate and oral absorption in humans. <i>J. Pharm. Sci.</i> 68(7), 850-852.			
		Sprowls (1963) <i>Prescription Pharmacy</i> . Philadelphia: Lippincott. Page cited: 56.			
		Voigt (1984) <i>Lehrbuch der Pharmazeutischen Technologie</i> , 5th ed. Basel: Verlag. Pages cited: 471, 472, 637.			
		Wade & Weller (1994) <i>Handbook of Pharmaceutical Excipients</i> , 2nd ed. Washington: American Pharmaceutical Association. Pages cited: v, vi (Contents pages), 141, 163, 252, 280, 433, 448.			
		Wadke <i>et al.</i> (1989) Preformulation testing. In Lieberman <i>et al.</i> , ed.: <i>Pharmaceutical Dosage Forms: Tablets</i> , Vol. 1. New York: Marcel Dekker. Pages cited: 5, 6.			
		Zhao <i>et al.</i> (1997) Effect of celecoxib, a novel COX-2 inhibitor, on health-related quality of life of patients with osteoarthritis of the knee. <i>Arthritis & Rheumatism</i> 40 (Suppl. 9), S88, abstract 348.			
Examiner			Date Considered		
*Examiner Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					